New drugs for multiple sclerosis: new treatment algorithms.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Early intervention with disease-modifying therapies is crucial for managing MS.
• Novel therapeutic targets are being explored for both relapsing and progressive forms of MS.

Purpose of the Study:

• To review recent updates in the multiple sclerosis (MS) treatment algorithm.
• To present emerging therapies currently undergoing clinical trials for MS.

Main Methods:

• Literature review of recent publications on MS treatment.
• Analysis of ongoing clinical trials for novel MS therapies.

Main Results:

• High-efficacy disease-modifying therapies show optimal benefit in the early inflammatory phase of MS.
• Bruton's tyrosine kinase (BTK) is a key emerging therapeutic target for relapsing and progressive MS.
• While remyelination therapies have shown limited broad success, targeted approaches offer potential for myelin repair.
• Interventions targeting Epstein-Barr virus (EBV) and gut microbiome dysbiosis are exploring links between microbial factors and MS.

Conclusions:

• A diverse range of treatments in development suggests a promising future for more effective MS therapies.
• Targeted approaches for remyelination and microbial interventions represent novel strategies in MS treatment.
• Continued research into new therapeutic targets and strategies is vital for advancing MS care.